{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:24:07Z","timestamp":1787509447203,"version":"build-2736575974"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13555-023-00956-6","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T03:02:15Z","timestamp":1688439735000},"page":"1661-1697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies"],"prefix":"10.1007","volume":"13","author":[{"given":"Natalie M.","family":"Fragoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Justin","family":"Gillenwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"12","key":"956_CR1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/S40265-021-01566-2","volume":"81","author":"P Aarts","year":"2021","unstructured":"Aarts P, Dudink K, Vossen ARJV, et al. Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa. Drugs. 2021;81(12):1397\u2013410. https:\/\/doi.org\/10.1007\/S40265-021-01566-2.","journal-title":"Drugs"},{"issue":"1","key":"956_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/JW9.0000000000000028","volume":"9","author":"B Cutler","year":"2023","unstructured":"Cutler B, Hagstrom E, Greiling TM. Deodorant\/antiperspirant use and hair removal practices for hidradenitis suppurativa: recommendations from a single-center survey. Int J Women\u2019s Dermatol. 2023;9(1): e028. https:\/\/doi.org\/10.1097\/JW9.0000000000000028.","journal-title":"Int J Women\u2019s Dermatol."},{"issue":"5","key":"956_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/EXD.12926","volume":"25","author":"J Boer","year":"2016","unstructured":"Boer J, Jemec GBE. Mechanical stress and the development of pseudo-comedones and tunnels in hidradenitis suppurativa\/acne inversa. Exp Dermatol. 2016;25(5):396\u20137. https:\/\/doi.org\/10.1111\/EXD.12926.","journal-title":"Exp Dermatol"},{"issue":"12","key":"956_CR4","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/EXD.14214","volume":"29","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa? 15\u00a0years after. Exp Dermatol. 2020;29(12):1154\u201370. https:\/\/doi.org\/10.1111\/EXD.14214.","journal-title":"Exp Dermatol"},{"issue":"1","key":"956_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/BJD.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340. https:\/\/doi.org\/10.1111\/BJD.18983.","journal-title":"Br J Dermatol"},{"issue":"6","key":"956_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989\u201394. https:\/\/doi.org\/10.1111\/jdv.13216.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"956_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/J.JID.2020.06.019","volume":"141","author":"JW Frew","year":"2021","unstructured":"Frew JW, Marzano AV, Wolk K, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141(2):316-324.e2. https:\/\/doi.org\/10.1016\/J.JID.2020.06.019.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"956_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/BJD.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803\u201313. https:\/\/doi.org\/10.1111\/BJD.20969.","journal-title":"Br J Dermatol"},{"issue":"12","key":"956_CR9","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1111\/JDV.18465","volume":"36","author":"VG Frings","year":"2022","unstructured":"Frings VG, Jopp L, Srivastava M, Presser D, Goebeler M, Schmidt M. Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022;36(12):2488\u201398. https:\/\/doi.org\/10.1111\/JDV.18465.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"956_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0203672","volume":"13","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Tomalin LE, Schultz G, et al. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS One. 2018;13(9): e0203672. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0203672.","journal-title":"PLoS One."},{"issue":"3","key":"956_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/BJD\/LJAC096","volume":"188","author":"SL Schell","year":"2023","unstructured":"Schell SL, Cong Z, Sennett ML, et al. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies. Br J Dermatol. 2023;188(3):407\u201319. https:\/\/doi.org\/10.1093\/BJD\/LJAC096.","journal-title":"Br J Dermatol"},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"110530","DOI":"10.1016\/J.MEHY.2021.110530","volume":"149","author":"DB Yidana","year":"2021","unstructured":"Yidana DB. Hidradenitis suppurativa\u2014the role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology. Med Hypotheses. 2021;149:110530. https:\/\/doi.org\/10.1016\/J.MEHY.2021.110530.","journal-title":"Med Hypotheses."},{"key":"956_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS10123559","author":"M Napolitano","year":"2021","unstructured":"Napolitano M, Fabbrocini G, Martora F, Picone V, Morelli P, Patruno C. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021. https:\/\/doi.org\/10.3390\/CELLS10123559.","journal-title":"Cells."},{"key":"956_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.140598","author":"L Guenin-Mac\u00e9","year":"2020","unstructured":"Guenin-Mac\u00e9 L, Morel JD, Doisne JM, et al. Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.140598.","journal-title":"JCI Insight."},{"issue":"1","key":"956_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1128\/AAC.03513-14","volume":"59","author":"AC Nilsson","year":"2015","unstructured":"Nilsson AC, Janson H, Wold H, et al. LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive Staphylococcus\u00a0aureus. Antimicrob Agents Chemother. 2015;59(1):145\u201351. https:\/\/doi.org\/10.1128\/AAC.03513-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"956_CR16","doi-asserted-by":"publisher","DOI":"10.5070\/D3265048772","author":"A Pona","year":"2020","unstructured":"Pona A, Quan EY, Cline A, Feldman SR. Review of the use of gentian violet in dermatology practice. Dermatol Online J. 2020. https:\/\/doi.org\/10.5070\/D3265048772.","journal-title":"Dermatol Online J."},{"key":"956_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFV133.489","author":"P Lentini","year":"2015","unstructured":"Lentini P, Retterer C, Bavari S, Cheronis J. In vivo and in vitro characterization of provodine, a long acting, alcohol-free professional antiseptic, against Ebola virus and other serious viral, bacterial and fungal pathogens. Open Forum Infect Dis. 2015. https:\/\/doi.org\/10.1093\/OFID\/OFV133.489.","journal-title":"Open Forum Infect Dis."},{"issue":"6","key":"956_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2340\/00015555-0749","volume":"89","author":"\u0141 Matusiak","year":"2009","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89(6):601\u20133. https:\/\/doi.org\/10.2340\/00015555-0749.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"956_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2340\/00015555-1492","volume":"93","author":"E Mozeika","year":"2013","unstructured":"Mozeika E, Pilmane M, N\u00fcrnberg BM, Jemec GBE. Tumour necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in hidradenitis suppurativa. Acta Derm Venereol. 2013;93(3):301\u20134. https:\/\/doi.org\/10.2340\/00015555-1492.","journal-title":"Acta Derm Venereol"},{"key":"956_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","volume":"103","author":"D Jim\u00e9nez-Gallo","year":"2018","unstructured":"Jim\u00e9nez-Gallo D, de la Varga-Mart\u00ednez R, Ossorio-Garc\u00eda L, Collantes-Rodr\u00edguez C, Rodr\u00edguez C, Linares-Barrios M. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine. 2018;103:20\u20134. https:\/\/doi.org\/10.1016\/j.cyto.2017.12.020.","journal-title":"Cytokine"},{"issue":"5","key":"956_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"2","key":"956_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.050.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"956_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/S40744-022-00432-1","volume":"9","author":"A Sabet","year":"2022","unstructured":"Sabet A, Dickerson DS, Kunina EE, Buccarello AL, Monnet J. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar MSB11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther. 2022;9(2):693\u2013704. https:\/\/doi.org\/10.1007\/S40744-022-00432-1.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"956_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/BCP.13039","volume":"82","author":"E Hyland","year":"2016","unstructured":"Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(\u00ae) in healthy subjects. Br J Clin Pharmacol. 2016;82(4):983\u201393. https:\/\/doi.org\/10.1111\/BCP.13039.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"956_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/BJD.18220","volume":"182","author":"J Hercogov\u00e1","year":"2020","unstructured":"Hercogov\u00e1 J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316\u201326. https:\/\/doi.org\/10.1111\/BJD.18220.","journal-title":"Br J Dermatol"},{"issue":"1","key":"956_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000511284","volume":"7","author":"P Esme","year":"2021","unstructured":"Esme P, Akoglu G, Caliskan E. Rapid response to certolizumab pegol in hidradenitis suppurativa: a case report. Ski Appendage Disord. 2021;7(1):58\u201361. https:\/\/doi.org\/10.1159\/000511284.","journal-title":"Ski Appendage Disord"},{"key":"956_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15782","author":"P Esme","year":"2022","unstructured":"Esme P, Akoglu G, Dalk\u0131ran CD, Caliskan E. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: a real-life experience. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15782.","journal-title":"Dermatol Ther."},{"issue":"4","key":"956_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000521860","volume":"8","author":"P Esme","year":"2022","unstructured":"Esme P, Botsali A, Akoglu G, Caliskan E. An anti-interleukin-17A monoclonal antibody, ixekizumab, in the treatment of resistant hidradenitis suppurativa: a case series. Skin Appendage Disord. 2022;8(4):342\u20135. https:\/\/doi.org\/10.1159\/000521860.","journal-title":"Skin Appendage Disord"},{"key":"956_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15401","author":"FJ Melgosa Ramos","year":"2022","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Mateu Puchades A. Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune-mediated diseases: report of two cases. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15401.","journal-title":"Dermatol Ther."},{"key":"956_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.098","author":"J Sabater Abad","year":"2019","unstructured":"Sabater Abad J, Matellanes Palacios M, Velasco Pastor M, Gimeno Carpio E. A case report of hidradenitis suppurativa treated with certolizumab. J Am Acad Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jaad.2019.10.098.","journal-title":"J Am Acad Dermatol."},{"key":"956_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14494","author":"JG Holm","year":"2020","unstructured":"Holm JG, J\u00f8rgensen AHR, Yao Y, Thomsen SF. Certolizumab pegol for hidradenitis suppurativa: case report and literature review. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.14494.","journal-title":"Dermatol Ther."},{"issue":"5","key":"956_CR32","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1111\/IJD.15742","volume":"61","author":"F Repetto","year":"2022","unstructured":"Repetto F, Burzi L, Ramondetta A, et al. Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa. Int J Dermatol. 2022;61(5):e182\u20134. https:\/\/doi.org\/10.1111\/IJD.15742.","journal-title":"Int J Dermatol"},{"key":"956_CR33","doi-asserted-by":"publisher","unstructured":"Tampouratzi E, Kanni T, Katsantonis J, Douvali T. Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches. F1000Research. 2020; https:\/\/doi.org\/10.12688\/f1000research.21216.2","DOI":"10.12688\/f1000research.21216.2"},{"issue":"5","key":"956_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/BCR-2022-249684","volume":"15","author":"S Konda","year":"2022","unstructured":"Konda S, Shetty N, Friedman B, Veenstra J. Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. BMJ Case Reports CP. 2022;15(5): e249684. https:\/\/doi.org\/10.1136\/BCR-2022-249684.","journal-title":"BMJ Case Reports CP."},{"issue":"4","key":"956_CR35","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/IJD.15286","volume":"60","author":"I Wohlmuth-Wieser","year":"2021","unstructured":"Wohlmuth-Wieser I, Alhusayen R. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol. 2021;60(4):e140\u20131. https:\/\/doi.org\/10.1111\/IJD.15286.","journal-title":"Int J Dermatol"},{"issue":"8","key":"956_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14656566.2022.2070429","volume":"23","author":"SX Chen","year":"2022","unstructured":"Chen SX, Greif C, Gibson RS, Porter ML, Kimball AB. Advances in biologic and small molecule therapies for hidradenitis suppurativa. Expert Opin Pharmacother. 2022;23(8):959\u201378. https:\/\/doi.org\/10.1080\/14656566.2022.2070429.","journal-title":"Expert Opin Pharmacother"},{"key":"956_CR37","doi-asserted-by":"publisher","unstructured":"Melendez-Gonzalez M del M, Hamad J, Sayed C. Golimumab for the treatment of hidradenitis suppurativa in patients with previous TNF-\u03b1 treatment failure. J Invest Dermatol. 2021;141(12):2975\u20132979. https:\/\/doi.org\/10.1016\/J.JID.2021.04.026","DOI":"10.1016\/J.JID.2021.04.026"},{"issue":"12","key":"956_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.dld.2016.09.010","volume":"48","author":"A Tursi","year":"2016","unstructured":"Tursi A. Concomitant hidradenitis suppurativa and pyostomatitis vegetans in silent ulcerative colitis successfully treated with golimumab. Dig Liver Dis. 2016;48(12):1511\u20132. https:\/\/doi.org\/10.1016\/j.dld.2016.09.010.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"956_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000343221","volume":"226","author":"HH van der Zee","year":"2013","unstructured":"van der Zee HH, Prens EP. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013;226(2):97\u2013100. https:\/\/doi.org\/10.1159\/000343221.","journal-title":"Dermatology"},{"key":"956_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15266","author":"FJM Ramos","year":"2022","unstructured":"Ramos FJM, Ruiz RG, Puchades AM. Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: report of two cases. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15266.","journal-title":"Dermatol Ther."},{"key":"956_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES10020455","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/BIOMEDICINES10020455.","journal-title":"Biomedicines."},{"key":"956_CR42","doi-asserted-by":"publisher","DOI":"10.5070\/D3263047978","author":"JK Nguyen","year":"2020","unstructured":"Nguyen JK, Schlichte MJ, Jogi R, Alikhan M, Patel AB. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. Dermatol Online J. 2020. https:\/\/doi.org\/10.5070\/D3263047978.","journal-title":"Dermatol Online J."},{"issue":"8","key":"956_CR43","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/J.JID.2019.10.024","volume":"140","author":"A Gottlieb","year":"2020","unstructured":"Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(8):1538-1545.e2. https:\/\/doi.org\/10.1016\/J.JID.2019.10.024.","journal-title":"J Invest Dermatol"},{"issue":"16","key":"956_CR44","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.3390\/IJMS23169479","volume":"23","author":"H Iznardo","year":"2022","unstructured":"Iznardo H, Puig L. IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications. Int J Mol Sci. 2022;23(16):9479. https:\/\/doi.org\/10.3390\/IJMS23169479.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"956_CR45","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ART.41953\/ABSTRACT","volume":"73","author":"A Winkler","year":"2021","unstructured":"Winkler A, Sun W, De S, et al. The interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. 2021;73(12):2206\u201318. https:\/\/doi.org\/10.1002\/ART.41953\/ABSTRACT.","journal-title":"Arthritis Rheumatol"},{"key":"956_CR46","doi-asserted-by":"publisher","unstructured":"Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30 Suppl 1(S1):8\u201317. https:\/\/doi.org\/10.1111\/EXD.14338","DOI":"10.1111\/EXD.14338"},{"issue":"4","key":"956_CR47","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","volume":"138","author":"T Kanni","year":"2018","unstructured":"Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting il-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795\u2013801. https:\/\/doi.org\/10.1016\/j.jid.2017.10.030.","journal-title":"J Invest Dermatol"},{"key":"956_CR48","unstructured":"Sun NZ, Ro T, Jolly P, Sayed CJ. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. 2017;10(9):36. \/pmc\/articles\/PMC5749618\/. Accessed March 12, 2023."},{"key":"956_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15743","author":"M Agud-Dios","year":"2022","unstructured":"Agud-Dios M, Arroyo-Andr\u00e9s J, Rubio-Mu\u00f1iz C, Postigo-Lorente C. Successful treatment of hidradenitis suppurativa and Crohn\u2019s disease with combined guselkumab and apremilast. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15743.","journal-title":"Dermatol Ther."},{"issue":"5","key":"956_CR50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4103\/IJDVL.IJDVL_147_16","volume":"83","author":"B Tekin","year":"2017","unstructured":"Tekin B, Salman A, Ergun T. Hidradenitis suppurativa unresponsive to canakinumab treatment: a case report. Indian J Dermatol Venereol Leprol. 2017;83(5):615\u20137. https:\/\/doi.org\/10.4103\/IJDVL.IJDVL_147_16.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"956_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15002","author":"N Akdogan","year":"2021","unstructured":"Akdogan N, Yalici-Armagan B, Dogan S, Y\u0131lmaz R. Severe hidradenitis suppurativa (acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab. Dermatol Ther. 2021. https:\/\/doi.org\/10.1111\/DTH.15002.","journal-title":"Dermatol Ther."},{"issue":"11","key":"956_CR52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/JAMADERMATOL.2017.2392","volume":"153","author":"C Houriet","year":"2017","unstructured":"Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases. JAMA Dermatol. 2017;153(11):1195\u20137. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2017.2392.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"956_CR53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1684\/ejd.2013.2018","volume":"23","author":"T Jaeger","year":"2013","unstructured":"Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa\u2014rapid response to canakinumab (anti-IL-1\u03b2). Eur J Dermatol. 2013;23(3):408\u201310. https:\/\/doi.org\/10.1684\/ejd.2013.2018.","journal-title":"Eur J Dermatol"},{"key":"956_CR54","doi-asserted-by":"publisher","unstructured":"Thomi R, Cazzaniga S, Morteza Seyed Jafari S, Schlapbach C, Hunger RE. Association of hidradenitis suppurativa with T helper 1\/T helper 17 phenotypes: a semantic map analysis. JAMA Dermatol 2018;154(5):592\u2013595. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2018.0141","DOI":"10.1001\/JAMADERMATOL.2018.0141"},{"key":"956_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/J.JDIN.2021.04.006","volume":"4","author":"RN Kaakati","year":"2021","unstructured":"Kaakati RN, Tanaka J, Liu B, et al. Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: a single institution retrospective cohort study. JAAD Int. 2021;4:18. https:\/\/doi.org\/10.1016\/J.JDIN.2021.04.006.","journal-title":"JAAD Int"},{"issue":"2","key":"956_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jaad.2017.03.016","volume":"77","author":"M Dany","year":"2017","unstructured":"Dany M, Elston D. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(2):268-273.e6. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.016.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"956_CR57","doi-asserted-by":"publisher","first-page":"e284","DOI":"10.1111\/JDV.16280","volume":"34","author":"A Gambardella","year":"2020","unstructured":"Gambardella A, Calabrese G, Di Brizzi EV, Alfano R, Argenziano G. A case of atopic dermatitis and hidradenitis suppurativa successfully treated with dupilumab. J Eur Acad Dermatol Venereol. 2020;34(6):e284\u20136. https:\/\/doi.org\/10.1111\/JDV.16280.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"956_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/CED.15387","author":"MK Cho","year":"2022","unstructured":"Cho MK, Shin JU, Kim DH, Lee HJ. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. Clin Exp Dermatol. 2022. https:\/\/doi.org\/10.1111\/CED.15387.","journal-title":"Clin Exp Dermatol."},{"key":"956_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15645","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, Simonetti O, et al. Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15645.","journal-title":"Dermatol Ther."},{"issue":"11","key":"956_CR60","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/JAMADERMATOL.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2021.2905.","journal-title":"JAMA Dermatol"},{"key":"956_CR61","unstructured":"Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo-controlled, multicenter studies. In: AAD Late-Breaking Research Program; 2023."},{"issue":"5","key":"956_CR62","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/J.JAAD.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2020.05.007.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"956_CR63","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/BJD.19478","volume":"184","author":"JW Frew","year":"2021","unstructured":"Frew JW, Navrazhina K, Sullivan-Whalen M, Gilleaudeau P, Garcet S, Krueger JG. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol. 2021;184(2):350\u20132. https:\/\/doi.org\/10.1111\/BJD.19478.","journal-title":"Br J Dermatol"},{"issue":"6","key":"956_CR64","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/1346-8138.15807","volume":"48","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Oyama N, Iino S, Shimizu C, Hasegawa M. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases. J Dermatol. 2021;48(6):916\u201320. https:\/\/doi.org\/10.1111\/1346-8138.15807.","journal-title":"J Dermatol"},{"issue":"6","key":"956_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/IJD.14792","volume":"59","author":"M Arenbergerova","year":"2020","unstructured":"Arenbergerova M, Arenberger P, Marques E, Gkalpakiotis S. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. Int J Dermatol. 2020;59(6):733\u20135. https:\/\/doi.org\/10.1111\/IJD.14792.","journal-title":"Int J Dermatol"},{"issue":"11","key":"956_CR66","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/J.JDCR.2020.08.033","volume":"6","author":"MW Tee","year":"2020","unstructured":"Tee MW, Avarbock AB, Ungar J, Frew JW. Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD case reports. 2020;6(11):1167\u20139. https:\/\/doi.org\/10.1016\/J.JDCR.2020.08.033.","journal-title":"JAAD case reports"},{"issue":"5","key":"956_CR67","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/JDV.17071","volume":"35","author":"M Kaul","year":"2021","unstructured":"Kaul M, Jarvis P, Rozenberg I, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35(5):1143\u201351. https:\/\/doi.org\/10.1111\/JDV.17071.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"956_CR68","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1111\/EXD.14619","volume":"31","author":"AB Kimball","year":"2022","unstructured":"Kimball AB, Loesche C, Prens EP, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol. 2022;31(10):1522\u201332. https:\/\/doi.org\/10.1111\/EXD.14619.","journal-title":"Exp Dermatol"},{"key":"956_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13756","author":"M Megna","year":"2020","unstructured":"Megna M, Ruggiero A, Di Guida A, Patr\u00ec A, Fabbrocini G, Marasca C. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.13756.","journal-title":"Dermatol Ther."},{"issue":"11","key":"956_CR70","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.36849\/JDD.2020.1123","volume":"19","author":"MI Gul","year":"2020","unstructured":"Gul MI, Singam V, Hanson C, Neill BC, Aires DJ, Rajpara AN. Remission of refractory PASH syndrome using ixekizumab and doxycycline. J Drugs Dermatol. 2020;19(11):1123. https:\/\/doi.org\/10.36849\/JDD.2020.1123.","journal-title":"J Drugs Dermatol"},{"key":"956_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jdcr.2020.12.036","volume":"9","author":"K Reardon","year":"2021","unstructured":"Reardon K, Levin J, Levin C. Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab. JAAD Case Reports. 2021;9:7\u20138. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.036.","journal-title":"JAAD Case Reports"},{"issue":"4","key":"956_CR72","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/J.CLINDERMATOL.2021.05.026","volume":"39","author":"M Iannone","year":"2021","unstructured":"Iannone M, Janowska A, Tonini G, Davini G, Dini V. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa. Clin Dermatol. 2021;39(4):701\u20132. https:\/\/doi.org\/10.1016\/J.CLINDERMATOL.2021.05.026.","journal-title":"Clin Dermatol"},{"issue":"6","key":"956_CR73","doi-asserted-by":"publisher","first-page":"788","DOI":"10.23736\/S0392-0488.18.06135-7","volume":"155","author":"G Odorici","year":"2020","unstructured":"Odorici G, Pellacani G, Conti A. Ixekizumab in hidradenitis suppurativa in a psoriatic patient. G Ital di Dermatologia e Venereol. 2020;155(6):788\u20139. https:\/\/doi.org\/10.23736\/S0392-0488.18.06135-7.","journal-title":"G Ital di Dermatologia e Venereol"},{"issue":"6","key":"956_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13089","volume":"32","author":"C Lanna","year":"2019","unstructured":"Lanna C, Mazzilli S, Zangrilli A, Bianchi L, Campione E. One drug and two diseases: a case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast. Dermatol Ther. 2019;32(6): e13089. https:\/\/doi.org\/10.1111\/DTH.13089.","journal-title":"Dermatol Ther."},{"issue":"1","key":"956_CR75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2018.12.017","volume":"81","author":"RG Casseres","year":"2019","unstructured":"Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol. 2019;81(1):265\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2018.12.017.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR76","unstructured":"Freeman S. Izokibep improves multiple psoriatic arthritis symptoms in phase 2 study. MDEdge Rheumatology. https:\/\/www.mdedge.com\/rheumatology\/article\/255199\/psoriatic-arthritis\/izokibep-improves-multiple-psoriatic-arthritis. Published 2022. Accessed March 18, 2023."},{"key":"956_CR77","unstructured":"ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa. https:\/\/www.prnewswire.com\/news-releases\/acelyrin-inc-announces-izokibep-achieves-hiscr100-responses-at-12-weeks-in-moderate-to-severe-hidradenitis-suppurativa-301775533.html. Accessed April 20, 2023."},{"issue":"10378","key":"956_CR78","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet (London, England). 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet (London, England)."},{"issue":"7","key":"956_CR79","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1111\/JDV.17178","volume":"35","author":"S Ribero","year":"2021","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441\u20132. https:\/\/doi.org\/10.1111\/JDV.17178.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"956_CR80","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/BJD.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609\u201311. https:\/\/doi.org\/10.1111\/BJD.17822.","journal-title":"Br J Dermatol"},{"issue":"6","key":"956_CR81","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/J.JAAD.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524\u20136. https:\/\/doi.org\/10.1016\/J.JAAD.2020.02.005.","journal-title":"J Am Acad Dermatol"},{"key":"956_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.18685","author":"FJ Melgosa Ramos","year":"2023","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Est\u00e9banez Corrales A, Mateu Puchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/JDV.18685.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"11","key":"956_CR83","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1111\/JDV.16605","volume":"34","author":"Z Reguia\u00ef","year":"2020","unstructured":"Reguia\u00ef Z, Fougerousse AC, Maccari F, B\u00e9cherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750\u20131. https:\/\/doi.org\/10.1111\/JDV.16605.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"956_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/S13555-023-00906-2","author":"P Fernandez-Crehuet","year":"2023","unstructured":"Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther (Heidelb). 2023. https:\/\/doi.org\/10.1007\/S13555-023-00906-2.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"956_CR85","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.36849\/JDD.6752","volume":"21","author":"E Gutierrez","year":"2022","unstructured":"Gutierrez E, Issa N, Resnik B. Novel regimen of IL-17A inhibitor secukinumab for the remission of severe hidradenitis suppurativa: case report. J Drugs Dermatol. 2022;21(12):1358\u201360. https:\/\/doi.org\/10.36849\/JDD.6752.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"956_CR86","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/BJD.15769","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182\u20135. https:\/\/doi.org\/10.1111\/BJD.15769.","journal-title":"Br J Dermatol"},{"issue":"8","key":"956_CR87","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/J.AD.2019.07.007","volume":"111","author":"I Villegas-Romero","year":"2020","unstructured":"Villegas-Romero I, Collantes-Rodr\u00edguez C, Valenzuela-Ubi\u00f1a S, Jim\u00e9nez-Gallo D. Moderate to severe hidradenitis suppurativa successfully treated with secukinumab. Actas Dermosifiliogr. 2020;111(8):696\u20138. https:\/\/doi.org\/10.1016\/J.AD.2019.07.007.","journal-title":"Actas Dermosifiliogr"},{"key":"956_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14205","author":"G Tas-Aygar","year":"2020","unstructured":"Tas-Aygar G, Gonul M, Ozcan I, Ayli MD, Ertoy-Baydar D. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.14205.","journal-title":"Dermatol Ther."},{"issue":"1","key":"956_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2340\/00015555-2794\/","volume":"98","author":"A Schuch","year":"2018","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151\u20132. https:\/\/doi.org\/10.2340\/00015555-2794\/.","journal-title":"Acta Derm Venereol"},{"key":"956_CR90","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen A-HR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018; https:\/\/doi.org\/10.1155\/2018\/8685136","DOI":"10.1155\/2018\/8685136"},{"issue":"4","key":"956_CR91","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5021\/AD.2018.30.4.462","volume":"30","author":"P Giuseppe","year":"2018","unstructured":"Giuseppe P, Nicola P, Valentina C, et al. A case of moderate hidradenitis suppurativa and psoriasis treated with secukinumab. Ann Dermatol. 2018;30(4):462. https:\/\/doi.org\/10.5021\/AD.2018.30.4.462.","journal-title":"Ann Dermatol"},{"issue":"11","key":"956_CR92","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/IJD.15209","volume":"59","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Garcovich S, Malvaso D, Giovanardi G, Peris K. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. Int J Dermatol. 2020;59(11):1423. https:\/\/doi.org\/10.1111\/IJD.15209.","journal-title":"Int J Dermatol"},{"key":"956_CR93","doi-asserted-by":"publisher","unstructured":"Nikolakis G, Kreibich K, Vaiopoulos A, et al. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. F1000Research. 2021; https:\/\/doi.org\/10.12688\/F1000RESEARCH.52100.2","DOI":"10.12688\/F1000RESEARCH.52100.2"},{"issue":"1","key":"956_CR94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/MRCR\/RXAB008","volume":"6","author":"AU Enginar","year":"2022","unstructured":"Enginar AU, Gundogdu M. Successful treatment of hidradenitis suppurativa with secukinumab in a patient with ankylosing spondylitis and familial mediterranean fever. Mod Rheumatol Case Rep. 2022;6(1):19\u201321. https:\/\/doi.org\/10.1093\/MRCR\/RXAB008.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"7","key":"956_CR95","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15507","volume":"35","author":"M Li","year":"2022","unstructured":"Li M, Xiang H, Liang Y, et al. Secukinumab for PASS syndrome: a new choice for therapeutic challenge? Dermatol Ther. 2022;35(7): e15507. https:\/\/doi.org\/10.1111\/DTH.15507.","journal-title":"Dermatol Ther."},{"key":"956_CR96","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13845","author":"A G\u0142owaczewska","year":"2020","unstructured":"G\u0142owaczewska A, Szepietowski JC, Matusiak \u0141. Severe hidradenitis suppurativa successfully treated with secukinumab. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.13845.","journal-title":"Dermatol Ther."},{"issue":"10284","key":"956_CR97","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397(10284):1564\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00440-2.","journal-title":"Lancet"},{"issue":"4","key":"956_CR98","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/S40744-021-00360-6","volume":"8","author":"SL Truong","year":"2021","unstructured":"Truong SL, Chin J, Liew DFL, et al. Systematic review and meta-analysis of inflammatory bowel disease adverse events with anti-interleukin 17A agents and tumor necrosis factor inhibitors in rheumatic disease and skin psoriasis. Rheumatol Ther. 2021;8(4):1603. https:\/\/doi.org\/10.1007\/S40744-021-00360-6.","journal-title":"Rheumatol Ther"},{"key":"956_CR99","doi-asserted-by":"publisher","DOI":"10.1111\/EXD.14789","author":"A Flora","year":"2023","unstructured":"Flora A, Kozera EK, Jepsen R, et al. Baseline clinical, hormonal and molecular markers associated with clinical response to IL-23 antagonism in hidradenitis suppurativa: a prospective cohort study. Exp Dermatol. 2023. https:\/\/doi.org\/10.1111\/EXD.14789.","journal-title":"Exp Dermatol"},{"key":"956_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/BJD\/LJAD010","volume":"00","author":"K Dudink","year":"2023","unstructured":"Dudink K, Bouwman K, Chen Y, et al. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Br J Dermatol. 2023;00:1\u20139. https:\/\/doi.org\/10.1093\/BJD\/LJAD010.","journal-title":"Br J Dermatol"},{"key":"956_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14930","author":"L Burzi","year":"2021","unstructured":"Burzi L, Repetto F, Ramondetta A, et al. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther. 2021. https:\/\/doi.org\/10.1111\/DTH.14930.","journal-title":"Dermatol Ther."},{"issue":"12","key":"956_CR102","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/CCR3.3090","volume":"8","author":"AHR J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen AHR, Holm JG, Thomsen SF. Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn\u2019s disease: report and systematic literature review of effectiveness and safety. Clin Case Reports. 2020;8(12):2874\u20137. https:\/\/doi.org\/10.1002\/CCR3.3090.","journal-title":"Clin Case Reports"},{"key":"956_CR103","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15558","author":"FJ Melgosa Ramos","year":"2022","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Mateu Puchades A, Alfageme Rold\u00e1n F. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/DTH.15558.","journal-title":"Dermatol Ther."},{"issue":"3","key":"956_CR104","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.15368","volume":"33","author":"M Kovacs","year":"2019","unstructured":"Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(3):e140\u20131. https:\/\/doi.org\/10.1111\/jdv.15368.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"956_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/09546634.2019.1654067","volume":"32","author":"HS Berman","year":"2021","unstructured":"Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn\u2019s disease. J Dermatolog Treat. 2021;32(2):261\u20133. https:\/\/doi.org\/10.1080\/09546634.2019.1654067.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"956_CR106","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/CED.14199","volume":"45","author":"N Kearney","year":"2020","unstructured":"Kearney N, Byrne N, Kirby B, Hughes R. Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. Clin Exp Dermatol. 2020;45(5):618\u20139. https:\/\/doi.org\/10.1111\/CED.14199.","journal-title":"Clin Exp Dermatol"},{"key":"956_CR107","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13456","author":"T Montero-Vilchez","year":"2020","unstructured":"Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4\u00a0weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.13456.","journal-title":"Dermatol Ther."},{"issue":"6","key":"956_CR108","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14180","volume":"33","author":"C Garcia-Melendo","year":"2020","unstructured":"Garcia-Melendo C, Vilarrasa E, Cubir\u00f3 X, Bittencourt F, Puig L. Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. Dermatol Ther. 2020;33(6): e14180. https:\/\/doi.org\/10.1111\/DTH.14180.","journal-title":"Dermatol Ther."},{"issue":"7","key":"956_CR109","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1111\/JDV.18033","volume":"36","author":"DO Croitoru","year":"2022","unstructured":"Croitoru DO, Seigel K, Nathanielsz N, et al. Treatment of severe hidradenitis suppurativa and fistulizing Crohn\u2019s disease with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(7):e563\u20135. https:\/\/doi.org\/10.1111\/JDV.18033.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"956_CR110","doi-asserted-by":"publisher","unstructured":"Martora F, Fabbrocini G, Marasca C, Battista T, Megna M. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on \u201cParadoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab.\u201d Clin Exp Dermatol 2023; https:\/\/doi.org\/10.1093\/CED\/LLAD082","DOI":"10.1093\/CED\/LLAD082"},{"key":"956_CR111","doi-asserted-by":"publisher","DOI":"10.1007\/S13555-023-00913-3","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Prens EP, Passeron T, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther (Heidelb). 2023. https:\/\/doi.org\/10.1007\/S13555-023-00913-3.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"956_CR112","doi-asserted-by":"publisher","DOI":"10.2340\/ACTADV.V102.2926","author":"F Repetto","year":"2022","unstructured":"Repetto F, Burzi L, Ribero S, Quaglino P, Dapavo P. Efficacy and safety of risankizumab in hidradenitis suppurativa: a case series. Acta Derm Venereol. 2022. https:\/\/doi.org\/10.2340\/ACTADV.V102.2926.","journal-title":"Acta Derm Venereol."},{"issue":"5","key":"956_CR113","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/BJD.19716","volume":"184","author":"E Marques","year":"2021","unstructured":"Marques E, Arenberger P, Smetanov\u00e1 A, Gkalpakiotis S, Zimov\u00e1 D, Arenbergerov\u00e1 M. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. Br J Dermatol. 2021;184(5):966\u20137. https:\/\/doi.org\/10.1111\/BJD.19716.","journal-title":"Br J Dermatol"},{"issue":"4","key":"956_CR114","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1111\/IJD.15704","volume":"61","author":"G Licata","year":"2022","unstructured":"Licata G, Gambardella A, Buononato D, et al. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int J Dermatol. 2022;61(4):e126\u20139. https:\/\/doi.org\/10.1111\/IJD.15704.","journal-title":"Int J Dermatol"},{"key":"956_CR115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/J.JDCR.2021.05.029","volume":"14","author":"A Flora","year":"2021","unstructured":"Flora A, Holland R, Smith A, Frew JW. Rapid and sustained remission of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with IL-23p19 antagonist (risankizumab). JAAD Case Reports. 2021;14:33. https:\/\/doi.org\/10.1016\/J.JDCR.2021.05.029.","journal-title":"JAAD Case Reports"},{"issue":"6","key":"956_CR116","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.15116","volume":"34","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro RD, Pensa C, Lambiase S, Candi E, Bianchi L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol Ther. 2021;34(6): e15116. https:\/\/doi.org\/10.1111\/DTH.15116.","journal-title":"Dermatol Ther."},{"issue":"2","key":"956_CR117","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1111\/AJD.13559","volume":"62","author":"Y Kok","year":"2021","unstructured":"Kok Y, Nicolopoulos J, Dolianitis C. Tildrakizumab as a potential long-term therapeutic agent for severe hidradenitis suppurativa: a 15\u00a0months experience of an Australian institution. Australas J Dermatol. 2021;62(2):e313\u20136. https:\/\/doi.org\/10.1111\/AJD.13559.","journal-title":"Australas J Dermatol"},{"key":"956_CR118","doi-asserted-by":"publisher","unstructured":"Hayran Y, All\u0131 N, Y\u00fccel, Akdo\u011fan N, Turhan T. Serum IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3 levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome. Arch Dermatol Res. 2020;312(3):187\u2013196. https:\/\/doi.org\/10.1007\/S00403-019-02012-W\/FIGURES\/4","DOI":"10.1007\/S00403-019-02012-W\/FIGURES\/4"},{"issue":"12","key":"956_CR119","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/JDV.14389","volume":"31","author":"R Thomi","year":"2017","unstructured":"Thomi R, Kakeda M, Yawalkar N, Schlapbach C, Hunger RE. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31(12):2091\u20136. https:\/\/doi.org\/10.1111\/JDV.14389.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"956_CR120","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/BJD.16019","volume":"178","author":"S Hessam","year":"2018","unstructured":"Hessam S, Sand M, Gambichler T, Skrygan M, R\u00fcddel I, Bechara FG. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol. 2018;178(3):761\u20137. https:\/\/doi.org\/10.1111\/BJD.16019.","journal-title":"Br J Dermatol"},{"issue":"26","key":"956_CR121","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMOA2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon S-E, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340. https:\/\/doi.org\/10.1056\/NEJMOA2111563.","journal-title":"N Engl J Med"},{"key":"956_CR122","doi-asserted-by":"crossref","unstructured":"Alavi A, Prens E, Kimball AB, et al. Spesolimab for hidradenitis suppurativa: a proof-of-concept study. In: American Academy of dermatology annual meeting. New Orleans, LA; 2023.","DOI":"10.25251\/skin.7.supp.286"},{"issue":"12","key":"956_CR123","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1016\/J.JID.2021.03.037","volume":"141","author":"LM Prens","year":"2021","unstructured":"Prens LM, Ardon CB, van Straalen KR, et al. No Evident systemic terminal complement pathway activation in hidradenitis suppurativa. J Invest Dermatol. 2021;141(12):2966-2969.e1. https:\/\/doi.org\/10.1016\/J.JID.2021.03.037.","journal-title":"J Invest Dermatol"},{"key":"956_CR124","unstructured":"Giamarellos-Bourboulis EJ, Jemec GBE, Prens EP, et al. Complement split product C5a is elevated in moderate and severe hidradenitis suppurativa: clinical improvement by targeted therapy coming from the SHINE Study. In: 10th European Hidradenitis Suppurativa (EHSF) e.V. Conference. 2021."},{"issue":"2","key":"956_CR125","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/BJD.16428","volume":"179","author":"T Kanni","year":"2018","unstructured":"Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179(2):413\u20139. https:\/\/doi.org\/10.1111\/BJD.16428.","journal-title":"Br J Dermatol"},{"issue":"9","key":"956_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203672","volume":"13","author":"LK Hoffman","year":"2018","unstructured":"Hoffman LK, Tomalin LE, Schultz G, et al. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS One. 2018;13(9): e0203672. https:\/\/doi.org\/10.1371\/journal.pone.0203672.","journal-title":"PLoS One."},{"key":"956_CR127","unstructured":"ChemoCentryx announces positive topline results of phase II AURORA clinical trial of avacopan in the treatment of hidradenitis suppurativa (HS). GlobeNewsWire. https:\/\/www.globenewswire.com\/news-release\/2020\/10\/28\/2116264\/19219\/en\/ChemoCentryx-announces-positive-topline-results-of-phase-II-AURORA-clinical-trial-of-avacopan-in-the-treatment-of-hidradenitis-suppurativa-HS.html. Published 2020. Accessed March 21, 2023."},{"issue":"1","key":"956_CR128","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/BJD.18877","volume":"183","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183(1):176\u20138. https:\/\/doi.org\/10.1111\/BJD.18877.","journal-title":"Br J Dermatol"},{"key":"956_CR129","unstructured":"InflaRx announces amendment of co-development agreement and additional equity investment by staidson in connection with regulatory filing in China for Anti-C5a-antibody for treatment of COVID-19. https:\/\/www.globenewswire.com\/en\/news-release\/2022\/12\/21\/2577789\/0\/en\/InflaRx-announces-amendment-of-co-development-agreement-and-additional-equity-investment-by-staidson-in-connection-with-regulatory-filing-in-China-for-Anti-C5a-antibody-for-treatme.html. Published 2021. Accessed March 26, 2023."},{"key":"956_CR130","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000187","author":"AV Marzano","year":"2014","unstructured":"Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore). 2014. https:\/\/doi.org\/10.1097\/MD.0000000000000187.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"956_CR131","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/ANNUREV-PHARMTOX-051921-085014","volume":"63","author":"JZ Haeggstr\u00f6m","year":"2023","unstructured":"Haeggstr\u00f6m JZ, Newcomer ME. Structures of leukotriene biosynthetic enzymes and development of new therapeutics. Annu Rev Pharmacol Toxicol. 2023;63(1):407\u201328. https:\/\/doi.org\/10.1146\/ANNUREV-PHARMTOX-051921-085014.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"956_CR132","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/J.JID.2020.04.011","volume":"140","author":"CA Penno","year":"2020","unstructured":"Penno CA, J\u00e4ger P, Laguerre C, et al. Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4. J Invest Dermatol. 2020;140(12):2421-2432.e10. https:\/\/doi.org\/10.1016\/J.JID.2020.04.011.","journal-title":"J Invest Dermatol"},{"key":"956_CR133","unstructured":"Kirby JS, Okun MM, Alavi A, et al. Janus kinase 1 inhibition with povorcitinib (INCB054707) in hidradenitis suppurativa: efficacy and safety during the open-label extension period of a phase 2 study. In: 12th Conference of the European hidradenitis suppurativa foundation; 2023:S-0906"},{"key":"956_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAD.2022.07.047","author":"E Kozera","year":"2022","unstructured":"Kozera E, Flora A, Frew JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/J.JAAD.2022.07.047.","journal-title":"J Am Acad Dermatol."},{"key":"956_CR135","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318\u2013328. https:\/\/www.clinexprheumatol.org\/abstract.asp?a=9615. Accessed March 26, 2023."},{"issue":"2","key":"956_CR136","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.JDCR.2019.10.010","volume":"6","author":"KT Savage","year":"2020","unstructured":"Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Reports. 2020;6(2):99\u2013102. https:\/\/doi.org\/10.1016\/J.JDCR.2019.10.010.","journal-title":"JAAD Case Reports"},{"key":"956_CR137","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.139930","author":"JE Gudjonsson","year":"2020","unstructured":"Gudjonsson JE, Tsoi LC, Ma F, et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI insight. 2020. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.139930.","journal-title":"JCI insight."},{"issue":"8","key":"956_CR138","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/J.TIPS.2014.05.007","volume":"35","author":"RL Geahlen","year":"2014","unstructured":"Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014;35(8):414. https:\/\/doi.org\/10.1016\/J.TIPS.2014.05.007.","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"956_CR139","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/ALL.15261","volume":"77","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton\u2019s tyrosine kinase inhibition\u2014an emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355\u201366. https:\/\/doi.org\/10.1111\/ALL.15261.","journal-title":"Allergy"},{"issue":"5","key":"956_CR140","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/CTS.13005","volume":"14","author":"M Kaul","year":"2021","unstructured":"Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756\u201368. https:\/\/doi.org\/10.1111\/CTS.13005.","journal-title":"Clin Transl Sci"},{"issue":"19","key":"956_CR141","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/BLOOD-2018-11-852491","volume":"133","author":"NT Connell","year":"2019","unstructured":"Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019;133(19):2027\u201330. https:\/\/doi.org\/10.1182\/BLOOD-2018-11-852491.","journal-title":"Blood"},{"issue":"2","key":"956_CR142","first-page":"170","volume":"18","author":"FR Kerdel","year":"2019","unstructured":"Kerdel FR, Azevedo FA, Kerdel Don C, Don FA, Fabbrocini G, Kerdel FA. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 Study. J Drugs Dermatol. 2019;18(2):170\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"956_CR143","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.JAAD.2018.06.046","volume":"80","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80\u20138. https:\/\/doi.org\/10.1016\/J.JAAD.2018.06.046.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"956_CR144","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","volume":"76","author":"P Weber","year":"2017","unstructured":"Weber P, Seyed Jafari SM, Yawalkar N, Hunger RE. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients. J Am Acad Dermatol. 2017;76(6):1189\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2017.02.026.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"956_CR145","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/J.AD.2020.06.006","volume":"112","author":"P Garbayo-Salmons","year":"2021","unstructured":"Garbayo-Salmons P, Exp\u00f3sito-Serrano V, Ribera Pibernat M, Roman\u00ed J. Hidradenitis suppurativa treated with apremilast: a case series. Actas Dermosifiliogr. 2021;112(10):936\u20139. https:\/\/doi.org\/10.1016\/J.AD.2020.06.006.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"956_CR146","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018991","volume":"99","author":"S Garcovich","year":"2020","unstructured":"Garcovich S, Giovanardi G, Malvaso D, De Simone C, Peris K. Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: case report and review of literature. Medicine (Baltimore). 2020;99(5): e18991. https:\/\/doi.org\/10.1097\/MD.0000000000018991.","journal-title":"Medicine (Baltimore)."},{"issue":"3","key":"956_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.13448","volume":"33","author":"I Proietti","year":"2020","unstructured":"Proietti I, Michelini S, Mambrin A, et al. A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS. Dermatol Ther. 2020;33(3): e13448. https:\/\/doi.org\/10.1111\/DTH.13448.","journal-title":"Dermatol Ther."},{"key":"956_CR148","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/J.JDCR.2021.08.031","volume":"16","author":"J McMichael","year":"2021","unstructured":"McMichael J, Stoff BK. Treatment of a perforating dermatosis with apremilast. JAAD Case Reports. 2021;16:155\u20137. https:\/\/doi.org\/10.1016\/J.JDCR.2021.08.031.","journal-title":"JAAD Case Reports"},{"key":"956_CR149","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.18812","author":"RB Warren","year":"2023","unstructured":"Warren RB, Strober B, Silverberg JI, et al. Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/JDV.18812.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"956_CR150","unstructured":"PTM-001\u2014PTM therapeutics. https:\/\/www.ptmthera.com\/ptm-001. Accessed January 8, 2023."},{"key":"956_CR151","unstructured":"Walker E. New start up aims to target inflammatory bowel disease. https:\/\/www.pathology.med.umich.edu\/news\/924. Published 2020. Accessed March 23, 2023."},{"key":"956_CR152","doi-asserted-by":"crossref","unstructured":"Liang TW, Presta LG, Brazil JC, Parkos CA, Cheng JC. Validation of hPTM-001, a humanized candidate therapeutic antibody for promoting mucosal wound healing in IBD. In: Crohn\u2019s and Colitis Congress; 2021.","DOI":"10.1053\/j.gastro.2021.01.136"},{"key":"956_CR153","doi-asserted-by":"publisher","first-page":"115175","DOI":"10.1016\/J.EJMECH.2023.115175","volume":"250","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kuang W, Wang D, Yuan K, Yang P. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers. Eur J Med Chem. 2023;250:115175. https:\/\/doi.org\/10.1016\/J.EJMECH.2023.115175.","journal-title":"Eur J Med Chem."},{"key":"956_CR154","unstructured":"Forman S, Patel DR, Kimball AB, et al. Safety and efficacy of LY3041658, a novel septa-specific monoclonal antibody to CXCR1 and CXCR2 ligands, in a phase 2 study in hidradenitis suppurativa. In: American Academy of Dermatology Annual Meeting 2023."},{"key":"956_CR155","doi-asserted-by":"publisher","unstructured":"Boyles JS, Beidler CB, Strifler BA, et al. Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody. MAbs. 2020; https:\/\/doi.org\/10.1080\/19420862.2020.1831880","DOI":"10.1080\/19420862.2020.1831880"},{"issue":"3","key":"956_CR156","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/EXD.12098","volume":"22","author":"BC Melnik","year":"2013","unstructured":"Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22(3):172\u20137. https:\/\/doi.org\/10.1111\/EXD.12098.","journal-title":"Exp Dermatol"},{"key":"956_CR157","unstructured":"Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa | BioSpace. https:\/\/www.biospace.com\/article\/releases\/-aclaris-therapeutics-announces-preliminary-topline-data-from-12-week-phase-2a-study-of-oral-zunsemetinib-ati-450-for-moderate-to-severe-hidradenitis-suppurativa\/. Accessed March 25, 2023."},{"key":"956_CR158","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/CPAA.S305308","volume":"13","author":"D Gordon","year":"2021","unstructured":"Gordon D, Hellriegel ET, Hope HR, Burt D, Monahan JB. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the MK2 inhibitor ATI-450 in healthy subjects: a placebo-controlled, randomized phase 1 study. Clin Pharmacol. 2021;13:123\u201334. https:\/\/doi.org\/10.2147\/CPAA.S305308.","journal-title":"Clin Pharmacol"},{"issue":"1","key":"956_CR159","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/BJD.19795","volume":"185","author":"K Wolk","year":"2021","unstructured":"Wolk K, Brembach TC, \u0160imait\u0117 D, et al. Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa. Br J Dermatol. 2021;185(1):164\u201376. https:\/\/doi.org\/10.1111\/BJD.19795.","journal-title":"Br J Dermatol"},{"key":"956_CR160","doi-asserted-by":"publisher","DOI":"10.1093\/BJD\/LJAD013","author":"C Gamell","year":"2023","unstructured":"Gamell C, Bankovacki A, Scalzo-Inguanti K, et al. CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/BJD\/LJAD013.","journal-title":"Br J Dermatol"},{"key":"956_CR161","doi-asserted-by":"publisher","unstructured":"Ben Abdallah H, Seeler S, Bregnh\u00f8j A, et al. Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation. Front Immunol. 2023; https:\/\/doi.org\/10.3389\/FIMMU.2023.1128897","DOI":"10.3389\/FIMMU.2023.1128897"},{"issue":"5","key":"956_CR162","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/BJD.20880","volume":"186","author":"A Bregnh\u00f8j","year":"2022","unstructured":"Bregnh\u00f8j A, Thuesen KKH, Emmanuel T, et al. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. Br J Dermatol. 2022;186(5):861\u201374. https:\/\/doi.org\/10.1111\/BJD.20880.","journal-title":"Br J Dermatol"},{"issue":"5","key":"956_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.11.061","volume":"78","author":"V De Vita","year":"2018","unstructured":"De Vita V, Melnik BC. Activated mTORC1 signaling: the common driving force of type 2 diabetes and hidradenitis suppurativa. J Am Acad Dermatol. 2018;78(5): e121. https:\/\/doi.org\/10.1016\/j.jaad.2017.11.061.","journal-title":"J Am Acad Dermatol."},{"issue":"5","key":"956_CR164","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jaad.2020.06.042","volume":"83","author":"T Bettuzzi","year":"2020","unstructured":"Bettuzzi T, Frumholtz L, Jachiet M, et al. Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa. J Am Acad Dermatol. 2020;83(5):1441\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.042.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"956_CR165","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/BJD.18003","volume":"181","author":"J Gottlieb","year":"2019","unstructured":"Gottlieb J, Madrange M, Gardair C, et al. PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens. Br J Dermatol. 2019;181(4):866\u20139. https:\/\/doi.org\/10.1111\/BJD.18003.","journal-title":"Br J Dermatol"},{"issue":"5","key":"956_CR166","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/J.1742-1241.2007.01318.X","volume":"61","author":"AY Chen","year":"2007","unstructured":"Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007;61(5):853. https:\/\/doi.org\/10.1111\/J.1742-1241.2007.01318.X.","journal-title":"Int J Clin Pract"},{"key":"956_CR167","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02062-19","author":"O Simonetti","year":"2020","unstructured":"Simonetti O, Lucarini G, Morroni G, et al. New evidence and insights on dalbavancin and wound healing in a mouse model of skin infection. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.02062-19.","journal-title":"Antimicrob Agents Chemother."},{"key":"956_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/FMICB.2021.749685","author":"A Oliva","year":"2021","unstructured":"Oliva A, Stefani S, Venditti M, Di Domenico EG. Biofilm-related infections in gram-positive bacteria and the potential role of the long-acting agent Dalbavancin. Front Microbiol. 2021. https:\/\/doi.org\/10.3389\/FMICB.2021.749685.","journal-title":"Front Microbiol."},{"issue":"11","key":"956_CR169","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/ANTIBIOTICS11111573","volume":"11","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, D\u2019Agostino GM, et al. The effect of dalbavancin in moderate to severe hidradenitis suppurativa. Antibiot (Basel, Switzerland). 2022;11(11):1573. https:\/\/doi.org\/10.3390\/ANTIBIOTICS11111573.","journal-title":"Antibiot (Basel, Switzerland)"},{"issue":"5","key":"956_CR170","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1684\/EJD.2022.4329","volume":"32","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, Simonetti O, et al. Successful use of dalbavancin in the management of severe hidradenitis suppurativa. Eur J Dermatol. 2022;32(5):645\u20136. https:\/\/doi.org\/10.1684\/EJD.2022.4329.","journal-title":"Eur J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00956-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00956-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T05:17:03Z","timestamp":1702703823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00956-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":170,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00956-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"2 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}